by Georgia Gowing, Macquarie University Dr. Alison Zhang. Credit: Macquarie UniversityAn international clinical trial of a treatment for advanced urothelial cancer has found a new dual therapy can nearly double patients’ life expectancy. The new immunotherapy is a combination of two drugs—enfortumab vedotin (EV) and pembrolizumab—delivered by infusion, and it is now being submitted to regulatory...
